← Search & browse all drugs

cathine

A08AA07

Forms & Strengths

Tablets: 10 mg, 20 mg (often formulated as norpseudoephedrine hydrochloride)

Adult Dosing

Short-term management of exogenous obesity: 10 to 20 mg orally once daily, typically taken in the morning
Maximum recommended duration is usually limited to a few weeks to minimize dependency and tolerance risks

Pediatric Dosing

Safety and efficacy not established in pediatric patients under 12 years of age
Not recommended for use in children

Indications

Short-term adjunct in the management of exogenous obesity as part of a comprehensive weight reduction regimen including caloric restriction and exercise

Mechanism of Action

Indirectly acting sympathomimetic amine
Stimulates the release of norepinephrine from storage sites in nerve terminals in the central nervous system
Suppresses appetite via action on the lateral hypothalamic feeding center

Contraindications

History of cardiovascular disease (e.g., arrhythmias, severe hypertension, coronary artery disease)
Advanced arteriosclerosis
Glaucoma
Hyperthyroidism
History of drug abuse or psychiatric illness
Concurrent use of or within 14 days following MAO inhibitors

Adverse Reactions

Central nervous system: Insomnia, nervousness, jitteriness, dizziness, euphoria, headache
Cardiovascular: Tachycardia, palpitations, elevated blood pressure, precordial pain
Gastrointestinal: Dry mouth, nausea, vomiting, diarrhea, constipation
Psychiatric: Psychosis, dependence, tolerance with prolonged use

Drug Interactions

Monoamine Oxidase Inhibitors (MAOIs): Risk of hypertensive crisis; contraindicated
Sympathomimetic agents: Enhances cardiovascular side effects such as hypertension and tachycardia
General anesthetics: Increased risk of cardiac arrhythmias
Antihypertensive agents: May antagonize the hypotensive effects of guanethidine, methyldopa, or beta-blockers

Curated Content: Needs Vetting Before Put to Clinical Use